Erlotinib (Tarceva) for advanced non-small cell lung cancer

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2005年 / 47卷 / 1205期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Erlotinib (Tarceva) is the second oral epidermal growth factor receptor (EGFR) inhibitor to become available in the US for treatment of advanced refractory NSCLC. In clinical trials, erlotinib produced a response rate of only 8.9%, but increased median survival from 4.7 to 6.7 months. Patients who had never smoked and those with EGFR-positive tumors survived longer. Erlotinib is generally well tolerated; diarrhea and rash are the most common adverse effects.
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [31] Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer
    Gerber, David E.
    Boothman, David A.
    Fattah, Farjana J.
    Dong, Ying
    Zhu, Hong
    Skelton, Rachel A.
    Priddy, Laurin L.
    Vo, Peggy
    Dowell, Jonathan E.
    Sarode, Venetia
    Leff, Richard
    Meek, Claudia
    Xie, Yang
    Schiller, Joan H.
    LUNG CANCER, 2015, 90 (03) : 534 - 541
  • [32] CHEMOTHERAPY VERSUS ERLOTINIB IN THE SECOND LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Fiala, Ondrej
    Pesek, Milos
    Krejci, Jana
    Sticha, Michal
    Minarik, Marek
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1259 - S1260
  • [33] Erlotinib effective against refractory bronchorrhea from advanced non-small cell lung cancer
    Thotathil, Ziad
    Long, Jeremy
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (09) : 881 - 882
  • [34] Efficacy of erlotinib and celecoxib for patients with advanced non-small cell lung cancer: A retrospective study
    Jin, Yi-Hua
    Li, Wei-Hong
    Bai, Yan
    Ni, Lei
    MEDICINE, 2019, 98 (10)
  • [35] Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study
    Giaccone, Giuseppe
    Ruiz, Marielle Gallegos
    Le Chevalier, Thierry
    Thatcher, Nick
    Smit, Egbert
    Rodriguez, Jose Antonio
    Janne, Pasi
    Oulid-Aissa, Dalila
    Soria, Jean-Charles
    CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6049 - 6055
  • [36] Sunitinib in Combination with Erlotinib for the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Thongprasert, Sumitra
    Govindan, Ramaswamy
    Krzakowski, Maciej
    Szczesna, Aleksandra
    Strausz, Janos
    Makhson, Anatoly
    Tye, Lesley
    Zhang, Ke
    Chao, Richard C.
    Scagliotti, Giorgio V.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S375 - S375
  • [37] Combination of quinacrine and erlotinib overcomes resistance to erlotinib in non-small cell lung cancer
    Dermavvan, Josephine Kam Tai
    Gurova, Katerina
    Pink, John
    Dowlati, Afshin
    De, Sarmishtha
    Naria, Goutham
    Sharma, Neelesh
    Stark, George
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [38] Predictors of erlotinib utilization and the impact of erlotinib use on overall survival in advanced, non-small cell lung cancer.
    Ersek, Jennifer L.
    Symanowski, James Thomas
    Kim, Edward S.
    Adams, Swann Arp
    Hebert, James R.
    Eberth, Jan Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Tarceva in relapsed non-small cell lung cancer:: experience from Northwest England
    Amir, E.
    Busato, S.
    Koehler, J.
    Lorigan, P.
    Thatcher, N.
    Blackhall, F.
    LUNG CANCER, 2008, 60 : S25 - S26
  • [40] Erlotinib (Tarceva) experience in a public health system, minority patient population with progressive metastatic non-small cell lung cancer (mNSCLC)
    Nathan, Sunita
    Patel, Pritesh
    Sharma, Jennifer
    Samuel, Joyce
    Stroger, John H., Jr.
    CHEST, 2007, 132 (04) : 588S - 589S
12345